PARTNERING WITH SANGAMO
Sangamo values partnerships with companies that share our mission of translating ground-breaking science into genomic medicines that transform patients’ lives. We seek collaborations that can leverage and extend our leading capabilities in gene therapy, cell therapy, genome editing, and genome regulation.
Interested in Partnering with Us?
Click here to contact Mark McClung, Executive Vice President, Chief Business Officer.
Takeda Pharmaceutical Company Limited
Takeda and Sangamo are developing therapeutics for Huntington's disease utilizing our ZFP-TF genome regulation platform.